

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-01-28** | Period of Report: **2013-01-27**
SEC Accession No. [0001193125-13-026330](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

SOLTA MEDICAL INC

CIK: **1171298** | IRS No.: **680373593** | State of Incorporation: **DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **001-33123** | Film No.: **13552538**
SIC: **3845** Electromedical & electrotherapeutic apparatus

Mailing Address
25881 INDUSTRIAL
BOULEVARD
HAYWARD CA 94545

Business Address
25881 INDUSTRIAL
BOULEVARD
HAYWARD CA 94545
5107822286

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

**January 27, 2013
Date of Report (date of earliest event reported)**

SOLTA MEDICAL, INC.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

001-33123
(Commission
File Number)

68-0373593
(I.R.S. Employer
Identification Number)

25881 Industrial Boulevard, Hayward, California 94545
(Address of principal executive offices)

(510) 782-2286
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On January 27, 2013, William Brodie advised Solta Medical, Inc. that he resigned from his position as Vice President of Global Sales. Mr. Brodie's role will be assumed by our President, Chief Executive Officer and Chairman, Stephen J. Fanning. Mr. Brodie has agreed to serve as a consultant for a period of 90 days to assist us in achieving an effective transition of his responsibilities.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SOLTA MEDICAL, INC.

Date: January 28, 2013

By: /s/ John F. Glenn

John F. Glenn

Chief Financial Officer